Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients

ConclusionWe demonstrated the efficacy of palonosetron in pediatric patients receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy and confirmed the appropriateness of the 20  μg/kg dose, regardless of age, considering the safety and pharmacokinetic profiles.Trial registrationJapicCTI-163305, registered 6 June 2016.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research